Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771547 | 1.00 | OPRK1 (0.54) | OPRK1OPRD1OPRL1OPRM1EGLN1 | |
| SCHEMBL13479986 | 0.91 | OPRL1 (0.60) | OPRK1OPRD1OPRL1OPRM1EGLN1 | |
| SCHEMBL21753390 | 0.89 | HDAC1 (0.48) | OPRK1OPRD1OPRL1OPRM1EGLN1 | |
| SCHEMBL5578720 | 0.89 | OPRK1 (0.50) | OPRK1OPRD1OPRL1OPRM1EGLN1 | |
| SCHEMBL10253956 | 0.89 | OPRL1 (0.48) | OPRK1OPRD1OPRL1OPRM1HDAC1 | |
| SCHEMBL3737310 | 0.88 | OPRK1 (0.49) | OPRK1OPRD1OPRL1OPRM1EGLN1 | |
| SCHEMBL3735215 | 0.88 | OPRL1 (0.48) | OPRK1OPRD1OPRL1OPRM1EGLN1 | |
| SCHEMBL13480119 | 0.86 | OPRL1 (0.54) | OPRK1OPRD1OPRL1OPRM1HDAC1 | |
| SCHEMBL14297231 | 0.85 | OPRK1 (0.49) | OPRK1OPRD1OPRL1OPRM1EGLN1 | |
| SCHEMBL14608881 | 0.85 | OPRK1 (0.54) | OPRK1OPRD1OPRL1OPRM1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122739-B1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2019-01-16 | — | — | EP | disclosed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| EP-3122739-A1 | PYRIDYL PIPERIDINES | Merck Patent GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015144290-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015144290-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | WO | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| EP-1943250-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-07-16 | — | — | EP | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | OXER1, OGFRL1, NR1H2 | OPRK1 20/4885OPRD1 15/4885OPRL1 6/4885 |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | OPRK1 129/4885OPRD1 123/4885OPRL1 63/4885 |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | OPRK1 287/4885OPRD1 824/4885OPRL1 347/4885 |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | WNT1, CTNNB1, WNT3 | OPRK1 1370/4885OPRD1 1217/4885OPRL1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.